Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells

Natalia Martin-Orozco¹, Yufeng Li², Yijun Wang², Shijuan Liu², Patrick Hwu², Yong-Jun Liu¹, Chen Dong¹, and Laszlo Radvanyi²

Abstract

CD⁴⁺CD₂⁵⁺Foxp³⁺ T-regulatory cells (Tregs) accumulate in tumors; however, little is known about how the tumor environment influences this process. Here we show that human melanomas express inducible T-cell costimulator ligand (ICOS-L/B7H) that can provide costimulation through ICOS for the expansion of activated Tregs maintaining high Foxp3 and CD25 expression as well as a suppressive function. Thus, ICOS-L expression by melanoma tumor cells may directly drive Treg activation and expansion in the tumor microenvironment as another mechanism of immune evasion. Cancer Res; 70(23): 1–10. ©2010 AACR.

Introduction

CD⁴⁺CD₂⁵⁺Foxp³⁺ T regulatory cells (Tregs) mediate immune suppression to control unfavorable immune responses against self-antigens or pathogens (1, 2). Tregs are found in high numbers in tumors of different tissue origin, and their presence correlates with poor antitumor immune response and poor prognosis (3–6). In melanomas, it has been reported that 25% of the CD⁴⁺ T cells found in tumors are Foxp3⁺, with only about 7% found in the peripheral blood of the same patients (7, 8). These results indicate that melanomas attract and retain Tregs in the tumor, or that tumor-infiltrating Tregs can expand in the tumor microenvironment. In addition, it has been reported that the tumor microenvironment can generate inducible Tregs from CD⁴⁺CD₂⁵⁻ T cells (9, 10), with the total pool of Tregs being composed, therefore, of both natural Tregs and newly arising induced peripheral Tregs (10–12).

Tregs, like other T cells, respond to T-cell receptor (TCR) stimulation and can be induced to expand with cytokines such as IL-2 (13, 14). Upon activation, Tregs also express costimulatory receptors, such as inducible T-cell costimulator (ICOS) and CD28, that further boosts their activation, proliferation, and survival (15). ICOS costimulation of CD⁴⁺ T cells has been found to facilitate the production of Th2 cytokines such as IL-4, IL-13, and IL-10 (16). Recently, a number of normal tissues have been reported to express ICOS-L, and regulate CD⁴⁺ T-cell activation and cytokine production (17–24). In several mouse models of autoimmunity, the CD⁴⁺CD₂⁵⁺ Tregs expressing ICOS were shown to produce IL-10 and control autoreactive T cells in the invaded organs such as the prediabetic pancreas (25, 26). Tregs present in melanoma have also been found to express ICOS on their surface (27), and ICOS⁺ Tregs have been shown to potentely inhibit T-cell responses indirectly through suppressing antigen-presenting cells with IL-10 (26, 27). In cancer, the source of ICOS costimulation for Tregs is largely unknown. Although DC, pDC, and B cells can express ICOS-L (16), there are no reports that ICOS-L expressed by tumor cells can regulate CD⁴⁺ T-cell activation, and the expression of ICOS-L in melanoma has not been characterized yet.

In this work, we report that both cultured and freshly isolated metastatic melanoma cells from stage IV melanoma patients express ICOS-L on their surface and can costimulate Tregs to promote high expression of CD25, Foxp3, and ICOS.

Materials and Methods

Cell lines

L cells transfected with CD32 and ICOS-L were a gift of Yong-Jun Liu. Melanoma tumor cell lines used in the study: WM35, WM35P1N1, WM35P2N1, A684, 888, 938, 624, WM793, WM793P1N1, WM793P2N1, A375, A375S2, 526, 2088, 2089, 2084, A681, A682, A687, 1007, MEMO, and SK-MEL-1.

Antibodies

ICOS-L, B7-H1, ICOS, CD86, Foxp3, rat IgG, and hamster IgG isotypes antibodies were from eblisience. Human leukocyte antigen (HLA) class II, CD4, CD25, CD45RA, CD45, CD8, CD16, IL-10, and IFN-γ antibodies were from BD Biosciences. Anti-MCP-1 (melanoma-associated chondroitin sulfate proteoglycan-1) was from Miltenyi Biotec. Cytokine analysis by intracellular staining was done using the Th1/Th2 kit (BioLegend).
cellular staining was done with a BD fixation/permeabilization kit.

**Quantitative real-time RT-PCR**

RNA was obtained using PureLink RNA mini-kit (Invitrogen) and RT was performed using Superscript RT First Strand (Invitrogen). Real-time PCR was then done using a Syber-Green based kit from BioRad. The primer sequences are ICOS-L: forward 5'-AGCGTGGAGGTACAC TGCATGTGGC-3', reverse 5'-GCTGACACGTGCTACCA AAGGGGCCGA-3'; B7-H1: forward 5'-GTCAAGGTTCCTCCAGGACC-3', reverse 5'- CAGTGACCTCGGCCTT GGG-3'; and actin: forward 5'- TTCTATGTGGGCGACGAGG-3', reverse 5'-ACTCCA TGCCCAGGAAGGAAG-3'.

**Screening of melanoma cell lines and primary melanomas for B7 molecule expression by flow cytometry**

Melanoma cell lines were harvested with protease-free dissociation buffer (Invitrogen). Metastatic melanoma tissue was obtained by surgical resection with patient informed consent using clinical and laboratory protocols approved by the M. D. Anderson Cancer Center Institutional Review Board (see Table 1). Tumor samples were processed within 2 hours of resection first by cutting them into 5–8 mm² pieces followed by mechanical disruption using a Seeward Stomacher (Fisher). The cell suspensions were applied over a 70% Ficoll-Isopaque layer and a cell suspensions were then applied over a 70% Ficoll-Isopaque layer and a cell suspensions were then applied over a 70% Ficoll-Isopaque layer -

<table>
<thead>
<tr>
<th>Tumor number</th>
<th>Location of metastasis</th>
<th>ICOS-L</th>
<th>B7-H1</th>
<th>HLA class II</th>
</tr>
</thead>
<tbody>
<tr>
<td>2033</td>
<td>Neck subcutaneous superior and inferior cervical lesion</td>
<td>Negative</td>
<td>P</td>
<td>High</td>
</tr>
<tr>
<td>2035</td>
<td>Left serratus: muscle under arm</td>
<td>Negative</td>
<td>P</td>
<td>High</td>
</tr>
<tr>
<td>2088</td>
<td>Abdomen: local fungating melanoma</td>
<td>Negative</td>
<td>N</td>
<td>Negative</td>
</tr>
<tr>
<td>2069</td>
<td>Neck</td>
<td>Low</td>
<td>N</td>
<td>Low</td>
</tr>
<tr>
<td>2089</td>
<td>Axillary lymph node</td>
<td>Low</td>
<td>P</td>
<td>Low</td>
</tr>
<tr>
<td>2097</td>
<td>Left arm: tumor mass</td>
<td>Low</td>
<td>P</td>
<td>Low</td>
</tr>
<tr>
<td>2016</td>
<td>Lung wedge</td>
<td>High</td>
<td>P</td>
<td>Low</td>
</tr>
<tr>
<td>2017</td>
<td>Parathyroid superficial</td>
<td>High</td>
<td>P</td>
<td>Low</td>
</tr>
<tr>
<td>2057</td>
<td>Lung nodule</td>
<td>High</td>
<td>P</td>
<td>High</td>
</tr>
<tr>
<td>2062</td>
<td>Uterus</td>
<td>High</td>
<td>N</td>
<td>High</td>
</tr>
<tr>
<td>2063</td>
<td>Occipital scalp mass</td>
<td>High</td>
<td>N</td>
<td>High</td>
</tr>
<tr>
<td>2082</td>
<td>Right leg: superficial</td>
<td>High</td>
<td>P</td>
<td>High</td>
</tr>
</tbody>
</table>

Abbreviations: N, negative; P, positive.

**Table 1. Tumor origin and expression of ICOS-L, B7-H1, and HLA class II**

blood mononuclear cells (PBMC) were purified using Miltenyi microbeads and further sorted into CD4⁺ and CD25⁺ and CD4⁺ CD25⁺ (Treg-enriched) subsets in a FACSaria (BD Biosciences). Cells were cultured together with irradiated melanoma or L cell lines and soluble anti-CD3 IgE (CLB-T3/4.E) at 20 ng/mL, or 100 ng/mL OKT-3. IL-2 (20 U/mL final) was added to all cultures. Where indicated, sorted cells were labeled with 1 μM carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) (Invitrogen). Five to six days later, the cells were analyzed for the expression of CD4, ICOS, CD25, and Foxp3. SB431542, a TGF-β1 kinase inhibitor, was used at 5 μM (Sigma-Aldrich). IL-10 and IFN-γ production was evaluated after activating the cultured cells for 6 hours with PMA+Ionomycin. Brefeldin A (Golgi-Stop; BD Biosciences) was added during the last hour of incubation. Cytokine staining was done using BD Fix/Perm reagents (BD Biosciences).

**Blockade of ICOS-L in a tumor mouse model**

C57BL/6 mice were injected intravenously (i.v.) with 10⁵ B16-OVA cells (day 0) followed by intraperitoneal (i.p.) transfer of 2 million CD4⁺ OT-II- Ly5.2 T cells on day 2. Starting on day 2, the mice were treated with 100 μg of anti-ICOSL antibody (28), or rat IgG, and thereafter for every 2 days until the end of the experiment on day 17. On day 17 after tumor challenge, Foxp3, CD25, CD4, and ICOS expression on T cells from lung tissues were evaluated by flow cytometry (29). C57BL/6 mice were purchased from the NCI and OT-II CD45.1 mice were from our colony.

**T-cell suppression assay**

For the T-cell suppression assays, the isolated Tregs from the cocultures were washed and rested in culture medium with no IL-2 for 1 day. Autologous-sorted CD4⁺ CD25⁺ cells labeled with CFDA-SE were cultured at a 1:1 ratio with the isolated and rested Tregs. An equal number of autologous-irradiated PBMC pulsed with 10 ng/mL of anti-CD3 were added, and the cultures incubated for 6 days. Cell division was analyzed by flow cytometry measuring CFDA-SE dilution.
levels of ICOS-L mRNA and negative ICOS-L cell surface expression such as WM35. Normal melanocytes showed low ICOS-L such as WM35 and some only a discrete or low expression (Supplementary Table 1). Some cells expressed high levels of ICOS-L mRNA expression (Fig. 1A) when compared with wild-type L cells, which correlated to the mRNA levels of expression in the different sets of all lines. The expression of L cells was considered 1 in all the analyses. B, protein expression of ICOS-L on melanoma cell lines. White histograms show anti ICOS-L and gray histograms isotype control. Normal melanocytes do not express ICOS-L (not shown).

Results

**ICOS-L is expressed by human melanoma cells**

While searching for the expression of B7 molecules in mouse tumors, we found that ICOS-L (also known as B7H, B7RP-1, GL50, or B7-H2) was expressed by the B16/F10 melanoma excised from C57BL/6 mice (Fig. S1). Then we checked whether human melanoma cells also express ICOS-L. We first analyzed mRNA expression of ICOS-L on a panel of melanoma cell lines, wild-type L cells, and L cells expressing ICOS-L. RT-PCR was performed for ICOS-L and $\beta$-actin genes. Data were normalized to the ACTB (j-actin) genes. Three separate graphs are shown to clearly illustrate the different levels of ICOS-L expression in the different sets of all lines. The expression of L cells was considered 1 in all the analyses.

**ICOS-L signaling delivered by melanoma cells promote sustained CD25 and Foxp3 expression by Tregs**

We next designed a series of experiments to test whether ICOS-L-expressing melanoma cells could provide costimulation to purified CD4$^+$ T cell populations. We sorted CD4$^+$CD25$^-$ (CD25$^-$) and CD4$^+$CD25$^{hi}$ (Treg-enriched) T
cells from peripheral blood of normal donors and cultured them with irradiated melanoma lines that were ICOS-L\(^+\) (WM35 or A684) or ICOS-L\(^-\) (WM793) and soluble anti-CD3 IgE (that stimulates human T cells in a soluble fashion; ref. 31) for 5 days. We used this IgE clone instead of OKT3 because the tumor cells do not express Fc receptors and cannot induce cross-linking of the CD3 complex with OKT3 (31). Immediately after sorting and after the coculture, the CD4\(^+\) T cells were analyzed for CD25, Foxp3, and ICOS expression. The initial CD25\(^-\) cells did not express Foxp3, whereas the CD25\(^+\) cells contained about 72% of Foxp3\(^+\) cells, which also had a fraction of 24% expressing ICOS (Fig. 3A top panels). This is similar to recently published results showing that a significant fraction of Tregs in the periphery can have ICOS expression (26). The CD25\(^-\) cells did not express ICOS (data not shown). After activation in the culture with all the melanoma lines, the CD25\(^-\) cells upregulated Foxp3 expression but only 6%–14% upregulated CD25 and this expression was not influenced by the ICOSL expression of the melanomas. Also the CD25\(^-\) cells only showed a 5%–10% increased of the ICOS\(^+\) cells (data not shown). Since activated CD4\(^+\) T cells can express low levels of Foxp3 (32, 33), these results suggest that the CD25\(^-\) cells have been recently activated and that our culture activation with the melanoma lines did not altered the capacity to induce Foxp3. For the CD25\(^+\) cells, although all the cells were CD25\(^+\) Foxp3\(^+\), the expression of Foxp3 increased to a higher level in about 45% of the cells (Foxp3\(^{hi}\) red gate in Fig. 3A) in the cocultures with ICOS-L\(^+\) melanoma lines, WM35 and A684 (Fig. 3A left panels). Also the cells that were Foxp3\(^{hi}\) had the higher expression of CD25. In contrast, CD25\(^-\) cells cultured with the ICOS-L\(^-\) melanoma line, WM793, only showed a 15% increase of Foxp3\(^{hi}\) cells and 29% of the cells started to lose CD25 expression by the end of the culture period. Therefore, ICOSL costimulation during activation of

Figure 2. Fresh melanoma cells express ICOS-L. A–C, ICOS-L, B7-H1, and HLA class II expression analysis from fresh melanoma samples. A, melanomas that did not express ICOS-L; B, samples that have low expression of ICOS-L; C, high ICOS-L expressing melanomas. White histograms show specific antibody staining, and gray histograms show isotype. D, summary of ICOS-L expression in fresh melanomas (n = 12).
Treg cells induces the high expression of Foxp3 and sustains the expression of CD25. In contrast, non-Treg CD25− cells upregulate Foxp3 to a lower level through activation of the TcR and independent of ICOS-L costimulation. We then analyzed the expression of ICOS in the Foxp3+ and Foxp3hi of the CD25− cells (blue gate) and Foxp3hi cells (red gate) on CD25+ cells are shown on the left panels. ICOS expression on Foxp3+ (blue gate) and Foxp3hi cells (red gate) on CD25+ cells are shown on the right panels. Therefore, we concluded that ICOS-L costimulation during the activation of Tregs positively induces the expression of Foxp3 and ICOS.

To confirm the Foxp3 induction by ICOS-L costimulation driven by melanoma lines, we generated melanoma cell lines that could express ICOS-L and human CD32 (Fc receptor) on their surface, such that the CD3 complex could be cross-linked on the T cells by OKT3 after CD32 binding with or without ICOS-L costimulation (Fig. S4A). WM793, which does not express ICOS-L, is used as a control.

**Figure 3.** A, ICOS-L costimulation by melanomas promotes high Foxp3 and CD25 expression on Tregs. Sorted CD4+CD25− (CD25−) and CD4+CD25+ (CD25+) cells were cultured with irradiated melanoma cell lines and anti-CD3. On day 5, the CD4+ cells were analyzed for the expression of Foxp3, CD25, and ICOS. ICOS-L+ tumors are WM35 and A684, and ICOS-L− cells are WM793. Foxp3 expression on sorted CD25− and CD25+ cells are shown on the left panels. ICOS expression on Foxp3+ (blue gate) and Foxp3hi cells (red gate) on CD25+ cells are shown on the right panels. B, percentage of CD4+CD25+ cells expressing high levels of Foxp3 from different donors (n = 10) cultured with melanoma lines that express (+) or do not express ICOS-L (−). C, sorted CD4+CD25− and CD4+CD25+ cells were labeled with CFDA-SE and activated with anti-CD3 over a monolayer of irradiated melanoma lines. After 5 days, the expression of Foxp3 and CFDA-SE dilution was analyzed. Where indicated the TGF-β-R1 kinase inhibitor SB431542 was added on day 1. D, patients with melanoma have high levels of Foxp3+ICOS+ T cells in the tumor infiltrates. TIL and PBMC from patients with stage IV metastatic melanoma were analyzed for the expression of CD4, CD25, Foxp3, and ICOS by flow cytometry. Shown are the percentages of CD25−Foxp3+ in the CD4+ population and the Foxp3+ICOS− cells in the CD4−CD25+ population.
express ICOS-L, was transfected with pcDNA3.2-CD32 with a empty pcDNA3.1 vector or with pcDNA3.1-ICOS-L and after selection and sorting, we obtained two cell lines designated as CD32\(^{\text{+}}\) WM793 and CD32\(^{\text{+}}\) ICOS-L\(^{\text{+}}\) WM793 (shown as ICOS-L\(^{\text{+}}\) WM793.CD32 in Fig. S4A). We used as reference L cells expressing CD32 and ICOSL (26; donated of Dr. Yong-Jun Liu, M. D. Anderson Cancer Center). After coculturing CD25\(^{\text{+}}\) and CD25\(^{\text{+}}\) T cells with these set of cell lines, we found that Foxp3\(^{\text{hi}}\) induction in the CD25\(^{\text{+}}\) cells was only present when cocultured with ICOS-L expressing cells (Fig. S4B, left panels) and that the Foxp3hi cells from these cultures had more than 80% ICOS\(^{\text{hi}}\) cells (Fig. S4B, right panels). For the CD25\(^{\text{+}}\) cells, we found that activation with WM793 and ICOSL\(^{\text{+}}\) WM793 generated about 18% Foxp3\(^{\text{hi}}\) cells and 46% CD25\(^{\text{+}}\) cells with no influence of ICOS-L. Thus, activation of Tregs with melanoma cells providing ICOS costimulation promotes the expansion of ICOS\(^{\text{+}}\) CD4\(^{\text{+}}\)CD25\(^{\text{hi}}\)Foxp3\(^{\text{hi}}\) T cells.

We next asked whether ICOS costimulation by ICOS-L\(^{\text{+}}\) melanoma cells could facilitate cell division of Tregs. Sorted CD4\(^{\text{+}}\)CD25\(^{\text{+}}\) and CD4\(^{\text{+}}\)CD25\(^{\text{+}}\) T cells were labeled with CFDA-SE and cultured over ICOS-L\(^{\text{+}}\) (WM35 and A684) or ICOS-L\(^{\text{+}}\) (WM793) melanoma cells. After 5 days in culture, more than 90% of the CD25\(^{\text{+}}\) T cells have divided and only 4% of the divided cells were Foxp3\(^{\text{hi}}\) in both ICOSL\(^{\text{+}}\) and ICOS-L\(^{\text{hi}}\) melanoma cell lines (Fig. 3C left panel). Similarly, CD25\(^{\text{+}}\) T cells cocultured with ICOS-L\(^{\text{+}}\) melanoma line showed more than 90% cell division with 12% of Foxp3\(^{\text{hi}}\) CFDA-SElow. In contrast, CD25\(^{\text{+}}\) T cells cocultured with ICOS-L\(^{\text{hi}}\) melanoma lines showed about 60% cell division with 40% of Foxp3\(^{\text{hi}}\) CFDA-SElow cells (Fig. 3C, middle panel). These results indicate that ICOS-L costimulation of Tregs slows the cell division rate and sustains Foxp3\(^{\text{hi}}\) expression. Since TGF-\(\beta\) has been found to induce Foxp3 expression in non-Tregs, we investigated the role of TGF-\(\beta\) signaling in our cocultures. For this, we used the TGF-\(\beta\) signaling inhibitor SB431542 (34) during the activation of CD25\(^{\text{+}}\) T cells with the ICOS-L\(^{\text{+}}\) melanoma cells. We found that the addition of SB431542 did not affect the cell division rate or the Foxp3 expression of the CD25\(^{\text{+}}\) T cells (Fig. 3C, right panel). Thus, the enhanced accumulation of divided CD4\(^{\text{+}}\)CD25\(^{\text{+}}\)Foxp3\(^{\text{hi}}\) Tregs induced by ICOS-L\(^{\text{+}}\) melanoma cells was not due to TGF-\(\beta\) secreted by the melanoma cell lines. Moreover, real-time RT-PCR analysis found that although WM35 does express a low level of the TGF-\(\beta\) gene, A684 cells are TGF-\(\beta\)-negative (data not shown). Thus, ICOS-L\(^{\text{+}}\) melanoma cells, although slowing down the cell division of Tregs, facilitated the maintenance of CD25 and high Foxp3 levels. When we studied 12 independent normal donor Tregs, we found that in all cases ICOS-L\(^{\text{+}}\) melanoma cell lines (WM35 and A684) facilitated increased expansion of Foxp3\(^{\text{hi}}\) CFDA-SElow cells compared with ICOS-L\(^{\text{hi}}\) WM793 cells (Fig. S5A). We did not see a difference in viability of both CD25\(^{\text{+}}\) and CD25\(^{\text{+}}\) T cells in these melanoma cocultures.

To confirm the role of ICOS costimulation in driving the expansion of Tregs with sustained and higher Foxp3 expression, we used OKT3 activation with ICOS-L-transduced L cells in CFDA-SE dilution assays. ICOS-L\(^{\text{+}}\) L cells facilitated a much higher rate of cell division of the CD25\(^{\text{+}}\) T cells (52.5%–90.8%; Fig. S5B). More specifically, 72% of the divided cells had high levels of Foxp3 expression compared with only 18% of the CD25\(^{\text{+}}\) cells that were cultured with L cells (Fig. S5B). Also the cells that have divided more showed the highest ICOS expression levels. As observed before, ICOS-L signaling did not alter the cell division or Foxp3 levels of CD25\(^{\text{+}}\) T cells.

The favorable cell division rate of CD25\(^{\text{+}}\) cells observed with ICOS-L\(^{\text{+}}\) L cells activation correlated with an increase in cell viability of about 19% on average (ICOS-L\(^{\text{+}}\) : 59.9 ± 1.83%, ICOS-L\(^{\text{+}}\) : 79.35 ± 7.56%, n = 5 experiments), whereas the viability of the CD25\(^{\text{+}}\) T cells was not affected by ICOS-L expression.

Next we asked whether patients with melanoma would have a CD25\(^{\text{+}}\) Foxp3\(^{\text{hi}}\) T cell population in the tumor environment. We isolated tumor-infiltrating lymphocytes (TIL) and PBMC from stage IV melanoma patients and analyzed T cell populations. We found that melanoma patients have 10 times more CD4\(^{\text{+}}\)CD25\(^{\text{+}}\) Foxp3\(^{\text{hi}}\) T cells in the TIL when compared with PBMC, and they also have increased numbers of these cells expressing ICOS (Fig. 3D). This suggests that the tumor environment indeed favors CD25\(^{\text{+}}\) Foxp3\(^{\text{hi}}\) ICOS\(^{\text{+}}\) T cell generation.

**Blockade of ICOS-L reduces the generation of CD4\(^{\text{+}}\)CD25\(^{\text{+}}\) Foxp3\(^{\text{hi}}\) ICOS\(^{\text{+}}\) T cells**

To confirm that Foxp3 induction in Treg cells is driven by ICOS-L stimuli, we sorted CD4\(^{\text{+}}\)CD25\(^{\text{hi}}\) T cells, labeled them with CFDA-SE and activated them with the tumors, as previously, but this time we added anti-ICOSL blocking antibody or mouse IgG. For these experiments, we used both normal donors and PBMC from stage IV melanoma patients. We found that blockade of ICOS-L reduced the generation of Foxp3\(^{\text{hi}}\)CFDA-SElow cells in normal donors by about 55% when the cells were cultured with ICOSL\(^{\text{+}}\) melanomas but did not alter the percentage of cells generated by ICOSL\(^{\text{+}}\) melanomas (Fig. 4A and B). Similar level of cell division and Foxp3 induction were found in cells from melanoma patients. These results indicate that a part of the Foxp3\(^{\text{hi}}\) Treg cells generated by activation with the tumors expressing ICOS-L is dependent on ICOS-L costimulation.

To further confirm that ICOS-L expressed by the tumor is involved in the appearance of Foxp3\(^{\text{hi}}\) cells in the tumor microenvironment, we made use of a mouse B16 melanoma model that expresses ICOS-L (see Fig. S1 in Supplementary data). C57BL/6 mice were injected i.v. with B16 cells expressing recombinant ovalbumin (B16-OVA) that provokes the development of tumor colonies in the lung. After 5 days, we transfer CD4\(^{\text{+}}\) T cells from OT-II TCR transgenic mice recognizing OVA\(_{251-264}\) peptide in context of H-\(\text{2}\)\(^{\text{b}}\) and that are congenic for CD45.1 (OT-II.CD45.1). Blocking antibodies against ICOS-L or rat IgG were administered every 2 days for 16 days starting 2 days before the tumor injection. We then evaluated Foxp3\(^{\text{hi}}\) T cells in the lung and found that both recipient CD45.1- and OVA-specific T cells had a reduced number of Foxp3\(^{\text{hi}}\) cells in the mice treated with anti-ICOS-L antibody (Fig. 4C). Also these cells had reduced expression of ICOS. Therefore, ICOS-L expression in the melanoma tumors promoted the expansion of Treg in the tumor environment.
Blockade of ICOSL reduces the induction of Foxp3\(^{hi}\)CD25\(^{hi}\) T-cells by melanomas. A–B, sorted CD4\(^{+}\)CD25\(^{+}\) cells from normal donors or melanoma patients were labeled with CFDA-SE and activated with anti-CD3 over a monolayer of irradiated melanoma lines, ICOS-L\(^{+}\) WM35 or ICOSL\(^{-}\) WM793. On day 1, mouse IgG or anti-ICOS-L antibody (MIH12) was added to the cultures. A, after 5 days, cells were analyzed for Foxp3 expression and CFDA-SE dilution. B, percentage of CD25\(^{hi}\) cells expressing high levels of Foxp3 and CFDA-SE\(^{low}\) from different donors (\(n = 5\)) cultured with ICOS\(^{+}\) or ICOSL\(^{-}\) melanomas and mouse IgG or anti-ICOSL antibodies. C, blockade of ICOS-L in vivo reduces the number of Foxp3\(^{+}\) ICOS\(^{+}\) T regs in the tumor tissue. Rat IgG or anti-ICOS-L was administered i.p. to C57BL/6 mice every 2 days for 16 days. Mice were i.v. injected with B16-OVA melanoma cells on day 2 and on day 7 mice were injected with 2 million OT-II-Ly5.1 CD4\(^{+}\) T cells. On day 17, lymphocytes from the lung were analyzed for the expression of CD45.1, CD4, CD25, Foxp3, and ICOS. Numbers in the plots are the percentage of Foxp3\(^{+}\) Tregs from Ly5.1\(^{+}\) (recipient Treg) and Ly5.1\(^{+}\) (OT-II T reg) CD4\(^{+}\) T cells. Numbers in the histogram show the percentage of ICOS\(^{+}\) T cells from CD4\(^{+}\) Foxp3\(^{+}\) cells. Graphs on the right show the percentage and total cell number of Foxp3\(^{+}\) cells from CD45.1\(^{-}\) and CD45.1\(^{-}\) cells in the lungs of all mice analyzed (\(n = 5\)).
We next tested the suppressive activity of the CD4+CD25+ T cells form the cocultures with ICOS-L+ WM793 or ICOS-L+ L cells. Autologous CD4+CD25+ T cells were CFDA-SE-labeled and cultured for 6 days with the activated CD4+CD25+ T cells at a 1:1 ratio. As shown in Fig. 5, CD4+CD25+ T cells activated with ICOS costimulation by ICOS-L+ WM793 cells had a similar (albeit slightly enhanced) suppressor cell activity as CD4+CD25+ T cells activated with ICOS-L+ WM793 cells, as indicated by the inhibition of CFDA-SE dilution in the CD4+CD25+ responder cells. Similar results were found when the CD4+CD25+ T cells were activated with ICOS-L+ L cells or control L cells (Fig. 5A).

ICOS costimulation has been shown to promote the expansion of Tr1-like CD4+ T cells and ICOS+ Tregs capable of IL-10 production (26). We found that ICOS-L-expressing melanoma cells and L cells induced the expansion of Tregs that produce IL-10. Activated CD4+CD25+ and CD4+CD25- cells cocultured with the indicated cell line were intracellular stained for IL-10 and IFN-γ.

**Discussion**

Costimulatory molecules of the B7 family control the activation of T cells during antigen recognition on APC and other tissues. In cancer, some of these B7 molecules can be immune suppressive and facilitate immune evasion. For example, the expression of B7-H1 in tumors, the ligand for PD1, inhibits the expansion and survival of antitumor T cells and is associated with worse prognosis (30, 35). The results presented in this paper demonstrate that in addition to B7-H1, a high proportion of human metastatic melanomas, as well as B16, a well-known murine melanoma, also express cell surface ICOS-L (B7H). It still remains unknown how ICOS-L expression is regulated in melanomas or normal melanocytes. We did not find ICOS-L induced expression in melanomas by a number of proinflammatory cytokines (e.g., IL-6, IL-1β, TNF-α, IFN-γ).
and we found that cultured normal melanocytes although having low mRNA levels of ICOS-L do not express ICOS-L protein. All the tumors analyzed were stage IV with no common tissue origin, which indicates that there may be some genetic component that determines ICOS-L expression.

ICOS-L expression in the tumor environment is a potential source of costimulation for the TIL. Some reports have shown that ICOS-L expressed on normal renal tubule epithelial cells (36), and gastric cancer cells, can induce the activation of IL-10–producing CD4+ T cells (17). In this study, we found that ICOS-L expressed by melanoma cells could costimulate Tregs to induce high levels of Foxp3, CD25, and ICOS. Our results suggest that tumor cells themselves may act as direct APC, since they can express HLA class II and provide self-antigen presentation and costimulation through ICOS-L. Interestingly, ICOS signaling allowed the expression of high levels of Foxp3 during cell division and also production of IL-10. In contrast, blockade of ICOS-L during T cell activation reduced Foxp3 expression but did not eliminate it, indicating that there are some other factor influencing Foxp3 expression, such as TCR signals (37) and perhaps other tumor factors. These results also indicate that in a more settle TCR activation the Tregs would require ICOS costimulation. Our results coincide with the finding that ICOS costimulatory signaling pathway drives Treg survival and expansion (26).

As found here and by others (27), Tregs coexpressing ICOS are elevated in TIL of melanoma patients, indicating an active presence of these cells in the tumor environment. Moreover, ICOS expression has been found in subsets of activated CD25+Foxp3+ Tregs (38) from peripheral blood. Taken together, these data indicate that ICOS+ Tregs are a subset of recently activated Tregs as a result of contact with tumor self-antigens and are critical in maintaining self-tolerance. This is in keeping with recent data showing an association of ICOS expression and IL-10–producing capacity in human Tregs and Tr1 cells (15, 26, 39). Data showing reduced ICOS+ Treg frequencies in the blood and tissues of patients with autoimmune diseases such as type I diabetes further support this contention (40).

It will be important to determine the levels of ICOS-L expression in a larger number of primary and metastatic melanoma samples and determine whether ICOS-L+ Tumor cells are associated with increased infiltrating Tregs and poorer overall survival. From a clinical standpoint, inhibition of ICOS expression or blocking ICOS costimulation may be of therapeutic benefit. We found that blockade of ICOS-L in vivo can in fact reduced Tregs in the tumor environment; however, careful dissection of the role of ICOS costimulation blockade on Tregs versus effector T cells needs to be addressed.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the melanoma TIL therapy team, D. Kentor for blood processing, and D. He, K. Dwyer, and K. Ramirez for cell sorting. We thank the Melanoma and Immunology Department members for help and discussion.

Grant Support

This work is supported in part by a NIH Melanoma SPORE Developmental grant (5 P50 CA093499-05-DPBP14) to L. Radvanyi and a grant from the Center for Targeted Therapy of MD Anderson Cancer Center (C. Dong and N. Martin-Orozco). L. Radvanyi also acknowledges support from the Miriam and Sheldon Adelson Medical Research Foundation (AMRF). C. Dong also acknowledges support from the Trust Fellowship of the M. D. Anderson Cancer Center.

Received 04/21/2010; revised 08/13/2010; accepted 09/09/2010; published OnlineFirst 11/23/2010.

References

2. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3hi T cells (36), and gastric cancer cells, can induce the expression of high levels of Foxp3, CD25, and ICOS. Our results suggest that tumor cells themselves may act as direct APC, since they can express HLA class II and provide self-antigen presentation and costimulation through ICOS-L. Interestingly, ICOS signaling allowed the expression of high levels of Foxp3 during cell division and also production of IL-10. In contrast, blockade of ICOS-L during T cell activation reduced Foxp3 expression but did not eliminate it, indicating that there are some other factor influencing Foxp3 expression, such as TCR signals (37) and perhaps other tumor factors. These results also indicate that in a more settle TCR activation the Tregs would require ICOS costimulation. Our results coincide with the finding that ICOS costimulatory signaling pathway drives Treg survival and expansion (26).

As found here and by others (27), Tregs coexpressing ICOS are elevated in TIL of melanoma patients, indicating an active presence of these cells in the tumor environment. Moreover, ICOS expression has been found in subsets of activated CD25+Foxp3+ Tregs (38) from peripheral blood. Taken together, these data indicate that ICOS+ Tregs are a subset of recently activated Tregs as a result of contact with tumor self-antigens and are critical in maintaining self-tolerance. This is in keeping with recent data showing an association of ICOS expression and IL-10–producing capacity in human Tregs and Tr1 cells (15, 26, 39). Data showing reduced ICOS+ Treg frequencies in the blood and tissues of patients with autoimmune diseases such as type I diabetes further support this contention (40).

It will be important to determine the levels of ICOS-L expression in a larger number of primary and metastatic melanoma samples and determine whether ICOS-L+ Tumor cells are associated with increased infiltrating Tregs and poorer overall survival. From a clinical standpoint, inhibition of ICOS expression or blocking ICOS costimulation may be of therapeutic benefit. We found that blockade of ICOS-L in vivo can in fact reduced Tregs in the tumor environment; however, careful dissection of the role of ICOS costimulation blockade on Tregs versus effector T cells needs to be addressed.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the melanoma TIL therapy team, D. Kentor for blood processing, and D. He, K. Dwyer, and K. Ramirez for cell sorting. We thank the Melanoma and Immunology Department members for help and discussion.

Grant Support

This work is supported in part by a NIH Melanoma SPORE Developmental grant (5 P50 CA093499-05-DPBP14) to L. Radvanyi and a grant from the Center for Targeted Therapy of MD Anderson Cancer Center (C. Dong and N. Martin-Orozco). L. Radvanyi also acknowledges support from the Miriam and Sheldon Adelson Medical Research Foundation (AMRF). C. Dong also acknowledges support from the Trust Fellowship of the M. D. Anderson Cancer Center.

Received 04/21/2010; revised 08/13/2010; accepted 09/09/2010; published OnlineFirst 11/23/2010.

References

2. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3hi T cells (36), and gastric cancer cells, can induce the expression of high levels of Foxp3, CD25, and ICOS. Our results suggest that tumor cells themselves may act as direct APC, since they can express HLA class II and provide self-antigen presentation and costimulation through ICOS-L. Interestingly, ICOS signaling allowed the expression of high levels of Foxp3 during cell division and also production of IL-10. In contrast, blockade of ICOS-L during T cell activation reduced Foxp3 expression but did not eliminate it, indicating that there are some other factor influencing Foxp3 expression, such as TCR signals (37) and perhaps other tumor factors. These results also indicate that in a more settle TCR activation the Tregs would require ICOS costimulation. Our results coincide with the finding that ICOS costimulatory signaling pathway drives Treg survival and expansion (26).

As found here and by others (27), Tregs coexpressing ICOS are elevated in TIL of melanoma patients, indicating an active presence of these cells in the tumor environment. Moreover, ICOS expression has been found in subsets of activated CD25+Foxp3+ Tregs (38) from peripheral blood. Taken together, these data indicate that ICOS+ Tregs are a subset of recently activated Tregs as a result of contact with tumor self-antigens and are critical in maintaining self-tolerance. This is in keeping with recent data showing an association of ICOS expression and IL-10–producing capacity in human Tregs and Tr1 cells (15, 26, 39). Data showing reduced ICOS+ Treg frequencies in the blood and tissues of patients with autoimmune diseases such as type I diabetes further support this contention (40).

It will be important to determine the levels of ICOS-L expression in a larger number of primary and metastatic melanoma samples and determine whether ICOS-L+ Tumor cells are associated with increased infiltrating Tregs and poorer overall survival. From a clinical standpoint, inhibition of ICOS expression or blocking ICOS costimulation may be of therapeutic benefit. We found that blockade of ICOS-L in vivo can in fact reduced Tregs in the tumor environment; however, careful dissection of the role of ICOS costimulation blockade on Tregs versus effector T cells needs to be addressed.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the melanoma TIL therapy team, D. Kentor for blood processing, and D. He, K. Dwyer, and K. Ramirez for cell sorting. We thank the Melanoma and Immunology Department members for help and discussion.

Grant Support

This work is supported in part by a NIH Melanoma SPORE Developmental grant (5 P50 CA093499-05-DPBP14) to L. Radvanyi and a grant from the Center for Targeted Therapy of MD Anderson Cancer Center (C. Dong and N. Martin-Orozco). L. Radvanyi also acknowledges support from the Miriam and Sheldon Adelson Medical Research Foundation (AMRF). C. Dong also acknowledges support from the Trust Fellowship of the M. D. Anderson Cancer Center.

Received 04/21/2010; revised 08/13/2010; accepted 09/09/2010; published OnlineFirst 11/23/2010.
Wahl P, Wuthrich RP. Role of the B7RP-1/ICOS pathway in renal
21.
22.
Klingenberg R, Autschbach F, Gleissner C, Giese T, Wambsganss N,
23.
Cancer Res; 70(23) December 1, 2010
24.
Cancer Research
25.
15. Haringer B, Lozza L, Steckel B, Geginat J. Identification and char-
acterization of IL-10/IFN-gamma-producing effector-like T cells with
26. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH,
et al. ICOS co-stimulatory receptor is essential for T-cell activation
28. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S,
et al. T helper 17 cells promote cytotoxic T cell activation in tumor
29. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S,
et al. T helper 17 cells promote cytotoxic T cell activation in tumor
30. Van Lier RA, Boot JH, De Groot ER, Aarden LA. Induction of T cell
33. Gavir MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-
35. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster
37. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy
38. Yang Q, Agematsu K, Freeman GJ, Tagawa Y, Sugane K, Hayashi T. The
39. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann
40. Schmidt J, Rakoczyevic G, Raju R, Dalakas MC. Upregulated inducible
41. Qian X, Aqmat J, Freeman GJ, Tagawa Y, Sugane K, Hayashi T. The
42. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann
43. Wiendl H, Mitsdoerffer M, Schneider D, et al. Muscle fibres and
cultured muscle cells express the B7.1/2-related inducible co-stimu-
latory molecule: implications for the pathogenesis of inflam-
44. Khayyamian S, Hutloff A, Buchner K, Grafe M, Henn V, Kroczek RA,
et al. ICOS-ligand, expressed on human endothelial cells, costimu-
lates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc
45. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy
permits regulatory T cells to surmount T cell receptor-specified
tional delineation and differentiation dynamics of human CD4+ T cells
47. Viera PL, Christensen JR, Minae S, O’Neill EJ, Barrat FJ, Boonstra A,
et al. IL-10-secreting regulatory T cells do not express Foxp3 but have
comparable regulatory function to naturally occurring CD4+ CD25+ T
R, Ilenio E, Urban M, et al. Diminished expression of ICOS, GITR and
CTLA-4 at the mRNA level in T regulatory cells of children with newly
Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells

Natalia Martin-Orozco, Yufeng Li, Yijun Wang, et al.

Cancer Res  Published OnlineFirst November 23, 2010.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1379

Supplementary Material  Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/11/23/0008-5472.CAN-10-1379.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.